Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Research and Innovation Action · Running

OperA Optimising Colorectal Cancer Prevention Trough Personalised Treatment with Artificial Intelligence

Coordinator
Universitetet I Oslo, Norway
Runs
1 September 2022 to 31 August 2027
Status
Running
EU funding
€4.7m
Total cost
€4.7m
Partners
19 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101057099

What the project is doing

In the project's own words, from its summary on CORDIS.

Integration of artificial intelligence (AI) technologies into clinical medicine has been hampered by challenges related to uncertain long-term clinical benefits, cost-effectiveness, and ethics/legal concerns. Application of AI in colonoscopy, a forefront research topic, has been also bothered by these issues. AI is, however, expected to reduce colorectal cancer incidence and mortality through personalised treatment. Our proposed project would change this discouraging situation and thus drastically improves colorectal cancer care.

We achieve the following goals: 1. Establish the value of AI-assisted colonoscopy in colorectal cancer prevention by conducting a pan-European, population-based, randomised trial with 222,000 participants. 2. Develop a colonoscopy AI risk-prediction tool for personalized treatment of colorectal polyps and cancer. 3. Develop cost-effectiveness models of AI-assisted colonoscopy in colorectal cancer screening. 4. Investigate ethical and legal barriers in AI development and implementation. 5.

Generate the first trustworthy and rapidly updating (?living?) clinical guidelines for AI in screening colonoscopy. 6. Develop a patient-oriented AI tool by including end-users in the process of AI development and communication. Our research consortium maximises the feasibility of the project, with world-class experts in gastroenterology, machine learning, cancer screening, biostatistics, disease modelling, regulatory science, and ethics and law in medicine from nine European countries, the US and Japan.

We also partner with a European medium-size AI enterprise for implementing the output of the project. The project has large potential impact on patients, society, and economy in Europe, and the World. Up to 6,000 fewer deaths due to colorectal cancer and saving of 720 million euro can be expected per year once the technology is widely accepted in Europe.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I OsloOsloNorwayCoordinator
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Humanitas Mirasole SpARozzano (Mi)ItalyParticipant
Showa UniversityTokyoJapanAssociatedpartner
Tokai National Higher Education Andresearch System, National University CorporationNagoyaJapanAssociatedpartner
Oslo Universitetssykehus HfOsloNorwayParticipant
Stiftelsen Magic Evidence EcosystemOsloNorwayParticipant
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie -Panstwowy Instytut BadawczyWarszawaPolandParticipant
Karolinska InstitutetStockholmSwedenParticipant
King's College Hospital Nhs Foundation TrustLondonUnited KingdomAssociatedpartner
Maplesoft Europe LimitedLondonUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomAssociatedpartner
Beth Israel Deaconess Medical Center, Inc Non Profit CorporationBoston MaUnited StatesParticipant
The Board of Trustees of the University of IllinoisUrbanaUnited StatesParticipant
The Pennsylvania State UniversityUniversity Park PaUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI